Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Generalized Pustular Psoriasis

Dermatologic

Generalized Pustular Psoriasis (GPP) Clinical Trials

Also called GPP, Pustular Psoriasis, von Zumbusch Psoriasis, DITRA, IL-36 Receptor Antagonist Deficiency, Acute Generalized Pustular Psoriasis

Ordinary psoriasis makes thick scaly plaques. Generalized pustular psoriasis is driven by a different part of the immune system and looks nothing like it.

In plain words, generalized pustular psoriasis is a rare form of psoriasis where an inflammation switch in the skin stays stuck on. During flares, painful pus-filled bumps spread over large areas of skin along with fever and chills.

Get an email when new Generalized Pustular Psoriasis trials open or the FDA decides. Get alerts

Generalized Pustular Psoriasis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review1

Imsidolimab, Dec 12, 2026

FDA-approved medicines1

Spevigo

Generalized Pustular Psoriasis has 1 FDA-approved medicine, 3 open or active clinical trials (2 recruiting), and a pending FDA decision on Imsidolimab, due Dec 12, 2026.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Generalized Pustular Psoriasis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Generalized Pustular Psoriasis

The pustules are sterile, meaning they contain white blood cells rather than bacteria, and they are not contagious. The whole body joins in: fever, a racing pulse, swollen skin that hurts to touch. Severe flares can lead to sepsis, dangerous drops in blood pressure, and kidney, lung or heart failure, which is why GPP is treated as a dermatologic emergency.

Keep reading about Generalized Pustular Psoriasis

The engine behind it is a signaling pathway called interleukin-36, or IL-36. Think of IL-36 as an inflammation switch in the skin and a protein called IL-36Ra as the hand that turns it off. In many people with GPP the off switch is weak or missing because of changes in the gene IL36RN. Changes in a second gene, CARD14, do the opposite job and push the inflammation switch on, and a third gene, AP1S3, has also been linked to the disease.

When the switch stays on, white blood cells flood the skin and form pustules. Many people with GPP have no detectable change in any of these genes, so the pathway can misfire for reasons that are still being worked out.

Diagnosis rests on the history of how the rash started, the appearance of the skin, and sometimes a skin biopsy. Blood tests alone cannot confirm it. Look-alike conditions include a drug reaction called AGEP and infected eczema, so a dermatologist with experience in pustular disease is worth seeking out.

What are the symptoms of Generalized Pustular Psoriasis?

These are common symptoms of Generalized Pustular Psoriasis, and how strong they are varies from person to person.

  • Crops of small pus-filled bumps (pustules) on red, tender skin, often across the trunk and limbs
  • Flares that build within a week, with fever, chills, headache and exhaustion
  • Burning, itching and pain in the affected skin
  • Skin that dries, scales and peels as the pustules clear
  • Joint pain, muscle weakness, nausea or diarrhea during a flare
  • Flares that return, from several a year to one every few years, each lasting weeks to months

Who gets Generalized Pustular Psoriasis?

GPP can start at any age but most often appears between 40 and 60, and women are affected slightly more often than men. About 3% of people with psoriasis develop a pustular form, and around half of people with GPP also have plaque psoriasis. People with a change in the IL36RN gene tend to develop it earlier, sometimes in childhood. Flares are often set off by something: an infection, stress, pregnancy (usually in the third trimester), low calcium, certain medicines, and the withdrawal of steroid tablets or injections.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Generalized Pustular Psoriasis?

There is currently 1 FDA-approved medication for Generalized Pustular Psoriasis.

spesolimab-sbzo
LEO Pharma Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Generalized Pustular Psoriasis medicines are in trials?

Investigational medicines Trial Friend tracks for Generalized Pustular Psoriasis, with trial results, safety findings and where each one stands.

How to get help paying for Generalized Pustular Psoriasis treatment

Charity funds and drugmaker programs for Generalized Pustular Psoriasis, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Generalized Pustular Psoriasis

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Generalized Pustular Psoriasis resources

Reputable organizations and medical references for learning more about Generalized Pustular Psoriasis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Generalized Pustular Psoriasis

Use this Generalized Pustular Psoriasis clinical trial finder to see the 2 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Imsidolimab (Quimilza), due December 12, 2026. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
Not yet recruitingObservational study, no treatment givenNo updates in a whileNCT07448428

Generalized Pustular Psoriasis Registry in Costa Rica

Sponsor: Caja Costarricense de Seguro Social

The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:

Ages not specified1 location
Expected to start May 2026Updated 8 months agoEst. May 2031 (~4y 6m)
RecruitingTreatment trialPhase 2Hasn't posted an update in over a yearNCT06231381

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

Intervention: HB0034, Placebo

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.

This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

Ages 18 Years to 75 Years2 locations
Started Feb 2024Updated 1 year agoEst. Feb 2025
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT04359394

International Rare And Severe Psoriasis Expert Network

Intervention: biological sampling, Phenotypic description, Photography

Sponsor: University Hospital, Basel, Switzerland · Boehringer Ingelheim

This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.

Ages 6 Months+
Started Sep 2021Updated 2 years agoEst. Dec 2030 (~4y 1m)
Find Generalized Pustular Psoriasis trials near you, ranked by distance →
Active trial locations11 cities
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+3 more

Trial Pipeline

Sep 2021 to May 2031
2022
2024
2026
2028
2030
now
Phase 2
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Generalized Pustular Psoriasis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Generalized Pustular Psoriasis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Generalized Pustular Psoriasis patient communities

Facebook groups, Reddit communities and YouTube channels where Generalized Pustular Psoriasis patients, caregivers and advocacy groups talk.

Generalized Pustular Psoriasis news and guides

Trial Friend articles about Generalized Pustular Psoriasis, newest first

Companies developing Generalized Pustular Psoriasis treatments

Drugmakers that list Generalized Pustular Psoriasis in their rare disease portfolio, 6 in all.

Questions people ask about Generalized Pustular Psoriasis